George C. Prendergast
George C. Prendergast | |
|---|---|
 | |
| Born | Philadelphia, Pennsylvania |
| Alma mater | Princeton University (PhD) Yale University (MS) University of Pennsylvania (BA) |
| Awards | 1995 Pew Scholar in the Biomedical Sciences |
| Scientific career | |
| Fields | Oncology, Molecular biology, Oncoimmunology |
| Institutions | Lankenau Institute for Medical Research DuPont Pharmaceuticals Company The Wistar Institute Merck Research Laboratories Howard Hughes Medical Institute |
George C. Prendergast, PhD (born 1961) is an American oncologist and biomedical scientist, currently President and CEO of Lankenau Institute for Medical Research (LIMR);[1] Co-leader of the Program in Cancer Cell Biology & Signaling at Kimmel Cancer Center, Thomas Jefferson University;[2] and former Editor-in-Chief of Cancer Research, the most highly cited journal in the field, a journal of the American Association for Cancer Research
Education and career
Born in Philadelphia, Pennsylvania in 1961, Prendergast graduated from the University of Pennsylvania in 1983 with a BA in Biochemistry. He earned an MS in molecular biophysics from Yale University in 1984 and a PhD in molecular biology from Princeton University in 1989.After receiving his doctorate, Prendergast continued his research as an American Cancer Society postdoctoral fellow at the Howard Hughes Medical Institute at NYU Medical Center.
Prendergast joined the Department of Cancer Research at Merck Research Laboratories as a staff scientist in 1991. In 1993, he returned to academic research at The Wistar Institute in Philadelphia, first as an assistant professor and later as an associate professor and assistant chair of the Tumor Biology Group. While at Wistar, in 1995, Prendergast was designated a Pew Scholar in the Biomedical Sciences.
In 1999, Prendergast left Wistar to become Senior Director of the Cancer Research Group at DuPont Pharmaceuticals Company. After the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb, Prendergast moved his groups at Wistar and DuPont to Lankenau Institute for Medical Research (LIMR) in 2002. He was appointed President and CEO of LIMR in 2004,.
Selected publications
- Muller, AJ; Duhadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC (2005). "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy". Nature Medicine. 11 (3): 312. doi:10.1038/nm1196. PMID 15711557.
- Prendergast, G; Ziff, E (1991). "Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region". Science. 251 (4990): 186. Bibcode:1991Sci...251..186P. doi:10.1126/science.1987636. PMID 1987636.
- Prendergast, GC; Lawe, D; Ziff, EB (1991). "Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation". Cell. 65 (3): 395. doi:10.1016/0092-8674(91)90457-A. PMID 1840505.
Honors
- 1995 - American Cancer Society Junior Faculty Award[citation needed]
- 1995 - Pew Scholar in the Biomedical Sciences Award[citation needed]
- 2003 - Highlighted Project, 2003 DoD Prostate Cancer Research Program Report[citation needed]
- 2008 - Special Achievement Award, Chinese Society for Clinical Oncology[citation needed]>
- 2008 - Designated One of the 250 Historically Most Influential Alumni of Princeton University[3]
- 2012 - Inventor of the Year, Thomas Jefferson University Kimmel Cancer Center[citation needed]
- 2014 - Highlighted 'In the Pipeline' Project, DoD Breast Cancer Research Program Report[citation needed]
- 2016 - First Designee of the Endowed Havens Chair for Biomedical Research
References
- ^ "The Lankenau Institute for Medical Research - George C. Prendergast, PhD". Retrieved 29 December 2013.
- ^ Program in Cancer Cell Biology & Signaling, Kimmel Cancer Center, Thomas Jefferson University
- ^ "Influential Princeton alumni". Princeton Alumni Weekly. January 23, 2008. Retrieved 29 December 2013.